Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of LY3209590 in Pediatric Type 2 Diabetes
NCT06362265Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2024
- Primary completion
- Jan 2026
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, single-arm trial of Insulin efsitora alfa in type 2 diabetes mellitus (T2DM), sponsored by Eli Lilly and Company. Primary endpoints: Area Under the Plasma Concentration Versus Time Curve at 65 days and Maximum Observed Plasma Concentration at 65 days. Started Oct 2024; status: completed.
02
Drugs
Insulin efsitora alfa
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06362265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06362265.